Heart failure & cardiomyopathies
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
Study context
- Population
- Adults with HFpEF/HFmrEF (LVEF >40%), elevated NT-proBNP and cardiovascular inflammation (high-sensitivity C-reactive protein ≥2 mg/l)ATHENA n = 673
- Planned comparison
- Ziltivekimab vs Placebo
- Primary endpoint
- ATHENA: change in KCCQ-Clinical Summary Score; HERMES: time to first composite of CV death, hospitalization for heart failure (HF) or urgent HF visit
- Follow-up
- ATHENA 12 months; HERMES event driven, minimum exposure 6 months
Methodological detailsATHENA and HERMES, international, multicentre, double-blind, placebo-controlled, HERMES event driven (∼845 adjudicated primary events)
- ATHENA and HERMES
- International
- Multicentre
- Double-blind
- Placebo-controlled
- HERMES event driven (∼845 adjudicated primary events)
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials. Eur J Heart Fail. Published 10 May 2026. doi:10.
Summarised from the published abstract; every number is checked against it